Zdrowie i gospodarka · 09/03/2018
FDA Clears DORYX MPC for Approval
The FDA has determined that DORYX MPC, a 60mg doxycycline hyclate delayed-release tablet, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Source: Federal Register — Food and Drug AdministrationOpen original release →